Intranasal mesenchymal stem cell treatment for neonatal brain damage: long-term cognitive and sensorimotor improvement
Vanessa Donega, Cindy T J van Velthoven, Cora H Nijboer, Frank van Bel, Martien J H Kas, Annemieke Kavelaars, Cobi J Heijnen, Vanessa Donega, Cindy T J van Velthoven, Cora H Nijboer, Frank van Bel, Martien J H Kas, Annemieke Kavelaars, Cobi J Heijnen
Abstract
Mesenchymal stem cell (MSC) administration via the intranasal route could become an effective therapy to treat neonatal hypoxic-ischemic (HI) brain damage. We analyzed long-term effects of intranasal MSC treatment on lesion size, sensorimotor and cognitive behavior, and determined the therapeutic window and dose response relationships. Furthermore, the appearance of MSCs at the lesion site in relation to the therapeutic window was examined. Nine-day-old mice were subjected to unilateral carotid artery occlusion and hypoxia. MSCs were administered intranasally at 3, 10 or 17 days after hypoxia-ischemia (HI). Motor, cognitive and histological outcome was investigated. PKH-26 labeled cells were used to localize MSCs in the brain. We identified 0.5 × 10(6) MSCs as the minimal effective dose with a therapeutic window of at least 10 days but less than 17 days post-HI. A single dose was sufficient for a marked beneficial effect. MSCs reach the lesion site within 24 h when given 3 or 10 days after injury. However, no MSCs were detected in the lesion when administered 17 days following HI. We also show for the first time that intranasal MSC treatment after HI improves cognitive function. Improvement of sensorimotor function and histological outcome was maintained until at least 9 weeks post-HI. The capacity of MSCs to reach the lesion site within 24 h after intranasal administration at 10 days but not at 17 days post-HI indicates a therapeutic window of at least 10 days. Our data strongly indicate that intranasal MSC treatment may become a promising non-invasive therapeutic tool to effectively reduce neonatal encephalopathy.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
References
- Dammann O, Ferriero D, Gressens P (2011) Neonatal encephalopathy or hypoxic ischemic encephalopathy? Appropriate terminology matters. Pediatr Res 70: 1–2.
- De Haan M, Wyatt JS, Roth S, Vargha-Khadem F, Gadian D, et al. (2006) Brain and cognitive-behavioural development after asphyxia at term birth. Dev Sci 9: 350–358.
- Ferriero DM (2004) Neonatal brain injury. N Engl J Med 351: 1985–1995.
- Graham EM, Ruis KA, Hartman AL, Northington FJ, Fox HE (2008) A systematic review of the role of intrapartum hypoxia-ischemia in the causation of neonatal encephalopathy. Am J Obstet Gynecol 199: 587–595.
- van Handel M, Swaab H, de Vries LS, Jongmans MJ (2007) Long-term cognitive and behavioural consequences of neonatal encephalopathy following perinatal asphyxia: a review. Eur J Pediatr 166: 645–654.
- Volpe JJ (2001) Perinatal brain injury: from pathogenesis to neuroprotection. Ment Retard Dev Disabil Res Rev 7: 56–64.
- Edwards AD, Brocklehurst P, Gunn AJ, Halliday H, Juszczak E, et al. (2010) Neurological outcomes at 18 months of age after moderate hypothermia for perinatal hypoxic ischaemic encephalopathy: synthesis and meta-analysis of trial data. BMJ 340: c363–370.
- Azzopardi DV, Strohm B, Edwards AD, Dyet L, Halliday HL, et al. (2009) Moderate hypothermia to treat perinatal asphyxial encephalopathy. N Engl J Med 361: 1349–1358.
- Borlongan CV, Weiss MD (2011) Baby STEPS: A giant leap for cell therapy in neonatal brain injury. Pediatr Res 70: 3–9.
- Lee JA, Kim BI, Jo CH, Choi CW, Kim EK, et al. (2010) Mesenchymal stem-cell transplantation for hypoxic-ischemic brain injury in neonatal rat model. Pediatr Res 67: 42–46.
- Pimentel-Coelho PM, Mendez-Otero R (2010) Cell therapy for neonatal hypoxic-ischemic encephalopathy. Stem Cells Dev 19: 299–310.
- Titomanlio L, Kavelaars A, Dalous J, Heijnen C, Baud O, et al. (2011) Stem cell therapy for neonatal brain injury: perspectives and challenges. Ann of Neurol 70: 698–712.
- van Velthoven CT, Kavelaars A, Heijnen CJ (2012) Mesenchymal stem cells as a treatment for neonatal ischemic brain damage. Pediatr Res 71: 474–481.
- van Velthoven CT, Kavelaars A, van Bel F, Heijnen CJ (2010) Mesenchymal stem cell treatment after neonatal hypoxic-ischemic brain injury improves behavioral outcome and induces neuronal and oligodendrocyte regeneration. Brain Behav Immun 24: 387–393.
- van Velthoven CT, Kavelaars A, van Bel F, Heijnen CJ (2010) Repeated mesenchymal stem cell treatment after neonatal hypoxia-ischemia has distinct effects on formation and maturation of new neurons and oligodendrocytes leading to restoration of damage, corticospinal motor tract activity, and sensorimotor function. J Neurosci 30: 9603–9611.
- van Velthoven CT, Kavelaars A, van Bel F, Heijnen CJ (2010) Nasal administration of stem cells: a promising novel route to treat neonatal ischemic brain damage. Pediatr Res 68: 419–422.
- Yasuhara T, Matsukawa N, Yu G, Xu L, Mays RW, et al. (2006) Behavioral and histological characterization of intrahippocampal grafts of human bone marrow-derived multipotent progenitor cells in neonatal rats with hypoxic-ischemic injury. Cell Transplant 15: 231–238.
- Yasuhara T, Hara K, Maki M, Mays RW, Deans RJ, et al. (2008) Intravenous grafts recapitulate the neurorestoration afforded by intracerebrally delivered multipotent adult progenitor cells in neonatal hypoxic-ischemic rats. J Cereb Blood Flow Metab 28: 1804–1810.
- Nadler JJ, Moy SS, Dold G, Trang D, Simmons N, et al. (2004) Automated apparatus for quantitation of social approach behaviors in mice. Genes Brain Behav 3: 303–314.
- Nijboer CH, Kavelaars A, Vroon A, Groenendaal F, van Bel F, et al. (2008) Low endogenous G-protein-coupled receptor kinase 2 sensitizes the immature brain to hypoxia-ischemia-induced gray and white matter damage. J Neurosci 28: 3324–3332.
- Ashley DM, Bol SJ, Waugh C, Kannourakis G (1993) A novel approach to the measurement of different in vitro leukaemic cell growth parameters: The use of PKH GL fluorescent probes. Leuk Res 17: 873–882.
- Auger CJ, Vanzo RJ (2005) Progesterone Treatment of Adult Male Rats Suppresses Arginine Vasopressin Expression in the Bed Nucleus of the Stria Terminalis and the Centromedial Amygdala. J of Neuroendoc 18: 187–194.
- Ferguson JN, Young LJ, Insel TR (2002) The neuroendocrine basis of social recognition. Front Neuroendocrinol 23: 200–224.
- Morgado-Bernal I (2011) Learning and memory consolidation: Linking molecular and behavioural data. Neurosci 176: 12–19.
Source: PubMed